Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday and set a price ...
Business Insider1mon
Rapport Therapeutics’ Promising Trial Results and Leadership Change
Rapport Therapeutics announced promising results from its PET and MAD-2 trials for RAP-219, a potential treatment for CNS disorders like focal epilepsy. The trials demonstrated that RAP-219 ...
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Thursday
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) will likely be posting its quarterly earnings results on Thursday, February 6th. Analysts expect Rapport Therapeutics to post earnings of ($0.62) ...